A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
第3相
完了
NCT03811535
| 対象疾患 | Growth Hormone Deficiency in Children |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Novo Nordisk A/S |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 200 名 |
|---|
| 介入（薬剤） | Somapacitan, Norditropin® |
|---|
| 開始日 | 2019年5月20日 |
|---|
| 完了日 | 2021年11月10日 |
|---|
| 結果公開日 | 2023年8月4日 |
|---|
概要
The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe). Researchers will test to see how well somapacitan works. The study will also test if somapacitan is safe. Participants will either get somapacitan or Norditropin® - which treatment participants get, is decided by chance. Both participants and the study doctor will know which treatment participants get. The study will last for 4 years. Participants will attend 19 clinic visits and have 1 phone call with the study doctor.
Height Velocity: In-trial Observation Period
From baseline (week 0) to visit 7 (week 52) · centimeters per year (cm/year)
| Norditropin | 11.8 ± 2.9 centimeters per year (cm/year) |
|---|
| Somapacitan | 11.2 ± 2.5 centimeters per year (cm/year) |
|---|
| Treatment difference | -0.5 (95% CI -1.1–0.2) |
|---|
Height Velocity: On-treatment Observation Period
From baseline (week 0) to visit 7 (week 52) · cm/year
| Norditropin | 11.8 ± 2.9 cm/year |
|---|
| Somapacitan | 11.2 ± 2.5 cm/year |
|---|
| Treatment difference | -0.5 (95% CI -1.1–0.2) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。